Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis

Tytuł:
A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis
Autorzy:
Jung JA
Kim TE
Lee H
Jeong BH
Park HY
Jeon K
Kwon OJ
Ko JW
Choi R
Woo HI
Koh WJ
Lee SY
Temat:
Therapeutics. Pharmacology
RM1-950
Źródło:
Drug Design, Development and Therapy, Vol 2015, Iss default, Pp 5433-5438 (2015)
Wydawca:
Dove Medical Press, 2015.
Rok publikacji:
2015
Kolekcja:
LCC:Therapeutics. Pharmacology
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1177-8881
Relacje:
https://www.dovepress.com/a-proposal-for-an-individualized-pharmacogenetic-guided-isoniazid-dosa-peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881
Dostęp URL:
https://doaj.org/article/a63527cde3b7417486d7149ceb56a1f6  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.63527cde3b7417486d7149ceb56a1f6
Czasopismo naukowe
Jin Ah Jung,1 Tae-Eun Kim,2 Hyun Lee,3 Byeong-Ho Jeong,3 Hye Yun Park,3 Kyeongman Jeon,3 O Jung Kwon,3 Jae-Wook Ko,4 Rihwa Choi,5 Hye-In Woo,6 Won-Jung Koh,3 Soo-Youn Lee4,5 1Department of Clinical Pharmacology, Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, Korea; 2Department of Clinical Pharmacology, Konkuk University Medical Center, 3Division of Pulmonary and Critical Care Medicine, Department of Medicine, 4Department of Clinical Pharmacology and Therapeutics, 5Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 6Department of Laboratory Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea Background/aim: Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment. However, treatment with INH is complicated by polymorphisms in the expression of the enzyme system primarily responsible for its elimination, N-acetyltransferase 2 (NAT2), and its associated hepatotoxicity. The objective of this study was to develop an individualized INH dosing regimen using a pharmacogenetic-driven model and to apply this regimen in a pilot study.Methods: A total of 206 patients with TB who received anti-TB treatment were included in this prospective study. The 2-hour post-dose concentrations of INH were obtained, and their NAT2 genotype was determined using polymerase chain reaction and sequencing. A multivariate regression analysis that included the variables of age, sex, body weight, and NAT2 genotype was performed to determine the best model for estimating the INH dose that achieves a concentration of 3.0–6.0 mg/L. This dosing algorithm was then used for newly enrolled 53 patients.Results: Serum concentrations of INH were significantly lower in the rapid-acetylators than in the slow-acetylators (2.55 mg/L vs 6.78 mg/L, median, P

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies